A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
ASLAN Pharmaceuticals
Start Date
October 24, 2017
End Date
December 1, 2020
Administered By
Duke Cancer Institute
Awarded By
ASLAN Pharmaceuticals
Start Date
October 24, 2017
End Date
December 1, 2020